Phospholipase A2 Receptor Antibodies, Serum [Test in Focus]
By Alyssa Frank • October 8, 2015
The new Phospholipase A2 Receptor Antibodies, Serum, test is now available to the Mayo Clinic practice and Mayo Clinic Laboratories clients. This test can be used to help distinguish primary from secondary membranous nephropathy. However, it should not be used as a stand-alone test but an adjunct to other clinical information.
Membranous nephropathy (MN) is a rare disease in which immune complexes deposit at the glomerular basement membrane, causing damage to the filtration barrier, resulting in proteinuria.
Approximately 70% to 75% of patients with primary membranous nephropathy are positive for anti-phospholipase A2 receptor (PLA2R) antibodies.
Anti-PLA2R antibodies are highly specific for the diagnosis of primary membranous nephropathy.
How to Use This Test
This test can be used to help distinguish primary from secondary membranous nephropathy. However, it should not be used as a stand-alone test but an adjunct to other clinical information.
There is evidence that levels of anti-PLA2R autoantibodies correlate well with membranous nephropathy activity and progression.
Absence of circulating anti- PLA2R autoantibodies does not rule out a diagnosis of primary MN.
An increase, decrease, or disappearance in antibody titer generally precedes a change in clinical status. Thus, antibody titer has a high predictive value with respect to clinical remission, relapse, or risk assessment after kidney transplantation.
EURO: Enzyme-Linked Immunosorbent Assay (ELISA)
SCOPE: Indirect Immunofluorescence Assay (IFA)
Day(s) and Time(s) Test Performed:
Samples will be batched and run Monday afternoon.
Up to 7 days
Alyssa Frank is a Marketing Segment Manager at Mayo Clinic Laboratories. She leads marketing strategies for product management and specialty testing. Alyssa has worked at Mayo Clinic since 2015.